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INTRODUCTION
Hepatitis B virus (HBV) infection is one of the most
frequent of viral infection affecting human beings world-
wide. An estimated 350 million persons or 5% world
population are chronically infected with HBV. HBV
infection is a serious health problem in Pasific-Asia.
Chronic prevalence of HBV in Asia is very high and
approximately 25% - 40% of chronic carriers would die
due to liver disease (cirrhosis with or without hepato-
cellular carcinoma).1-6 Mean while in Indonesia, about 4%
from general population of people beyond 15 years old
had already been infected.
The pattern of HBV infection in Asian people is
different from those in western countries. In Asia, most
people usually got infected because they were born from
HBV infected mothers. They also rarely had acute
clinical syndrome, but infected chronically and at high risk
of developing cirrhosis and hepatocellular carcinoma
(HCC). In western population, HBV infection is
commonly seen in injecting drug user and sexual
transmitted. Acute clinical syndrome is a common
feature and rarely become chronic disease. These
differences were assumed by the experts to influence
treatment response.3
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ABSTRACT
Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment of chronic
HBV (Hepatitis B virus) infection had not shown satisfactory result. Monotherapy with alpha
interferon or lamivudine have been widely used as treatment of chronic HBV. However, treatment response to
Alpha interferon in Asian people was not satisfactory (15% - 20%), while monotherapy with lamivudine was
not sufficient to eradicate HBV in chronically infected patients and commonly induce drug resistance.
The occurrence of chronic hepatitis B resistant to lamivudine had encouraged development of newer agents
such as adefovir, entecavir, emtricitabine and nucleoside analog. New therapeutic strategy using combination
therapy should be considered if there is no sufficient response to monotherapy.
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Current treatment of chronic HBV infection that has
been widely recommended are interferon (IFN-α) and
lamivudine. Treatment response to IFN- α in Asian people
was not satisfactory (15 - 20%), while monotherapy with
lamivudine was not sufficient to eradicate HBV in
chronically infected patients.1 Combination therapy of new
class of various drugs with various mechanisms such as
adefovir dipivoxil, entecavir, emtricitabine and nucleoside
analog had shown better results.1,7 In this paper will be
discussed about various drugs used in new therapeutic
strategies for HBV infection and their treatment response.
CHARACTERISTICS
HBV belongs to the family of hepadnavirus and its
genome is a relaxed circular, partially double stranded
DNA of approximately 3,200 - 3,500 base pairs. There
are partially 4 partially overlapping open reading frames
encoding the envelope (S-surface), core (C), polymerase,
and X viral protein gen.8
The replication cycle of HBV begins with
the attachment of the virion to the hepatocyte.
The synthesis of the plus strand HBV DNA is completed
and the viral genome is converted into a covalently closed
circular DNA (cccDNA).9 In the early stage of
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replication, mRNA molecules which has varied length of
chain is originated from negative chain of cccDNA.
Among them is pre-genomic RNA which had longer chain
than RNA. This pre-genomic RNA is transferred into
cytoplasm and functions as mRNA for abundant viral
protein including HBsAg, HBcAg and considerable
amount of DNA polymerase/reverse transcriptase.
Reverse transcriptase will bind with its own mRNA and
direct mRNA complex polymerase into immature viral
nucleocapsid inside the cytoplasm. Pre-genomic RNA is
reverse transcribed into the minus strand HBV DNA in
the nucleocapsid and at the same time its RNA will be
degraded. Minus strand HBV DNA will form positive
partially long chained strand HBV DNA. Some part of
double stranded DNA will migrate into endoplasm
reticulum, where it receives its capsule and become
complete virion and ready to enter the blood circulation.
However, some of double stranded DNA will be
transported from cytoplasm into the nucleus and form
more cccDNA, thus it will have more restored
intranuclear cccDNA. In single hepatocyte, it is predicted
to have 10-50 copies of cccDNA.9
In human, the virus is found in blood and any body
fluid such as saliva, semen, nasopharingeal secret and
menstrual fluid. Sometimes it can also be found in urine,
bile salt, pancreatic secret, pleural fluid, ascitic fluid,
 cerebrospinal fluid, lacrimal secret, breast milk but not
gastric fluid.
IMMUNOPATHOGENESIS10
The virus enters the susceptible body through
injection or skin. In the body, it is transferred to the liver
as its main site of infection via blood circulation. Virus
replicates in the liver efficiently mainly involving
hepatocytes. One single virion is already sufficient to cause
infection. Viremia may reach > 109 virion/ml and
disseminate to other organs such as kidney, pancreas,
testis, ovary, spleen and lymphoid glands. It remains
unclear whether the immunologic activation is taken place
in the liver or other site during primary infection.
Whatever the exact mechanism is, immune response is
strongly directed to the infected liver.
Hepatocelullar damage is predicted begin with
recognizing by T cell cytotoxic through specific antigen
(CTLs) which induces positive hepatocyte apoptosis.
Cytotoxic T lymphocyte (CTL) will then mobilize
non-specific inflammatory cells (macrophage, neutrophill
and other lymphocytes) and make focal
necroinflammation. Infiltration of inflammatory cells has
role in hepatocelullar death. At this phase, clinical
symptoms of hepatitis become apparent and together with
elevation of aminotransferase enzyme. During limited
acute infection, pathologic appearance is mild to
moderate and viral replication is effectively controlled by
host immune response and hepatitis will resolve.
In some conditions, nonspecific viral response will be
enhanced by unclear host determinants or by viral
factor which causes massive hepatocellular damage and
fulminant hepatitis. On the other hand, chronic hepatitis
occurs due to persistent liver damage caused by
ineffective viral clearance. In carriers without symptoms,
tolerance to HBV Ag is mild or does not cause damage in
infected liver. Infected subjects with VHB may give strong
immunologic response, both to CD4+ and CD+8 which
are multispesific and polyclonal cellular to HBV. Inversely,
those with chronic infection showed weak or no anti-HBV
response.
During HBV acute infection, T helper (Th) response,
MCHC-2 CD+4 dependent to multiple epitope of HBcAg/
HBeAg are predominant in all patients. Response to
envelope Ag HBV is not apparent. What makes
the disparity remains unclear because patients who had
already vaccinated with HBsAg could induce CD+4
responses which restricted MHC-2 to VHB envelope
protein. It is possible that T-cell anti-envelope response
had occurs early during primary infection but tolerant or
exhausted to high titer viral antigen exposure or improper
antigen presentation to immune system. The absence of
relative anti-envelope T cell response has important role
in controlling viral infection although nucleocapsid MHC-
dependent CD+4 involved in immunoregulatory system.
By helping B cell to form anti envelope Ab and HBV-
specific CTL activation,  Th CD+4 may directed early
antiviral response. During chronic infection of HBV, strong
specific response CD+4 will be exhausted or non
responsive. The cause of these molecular changes is not
clear yet. CTL is involved in reaction to intracellular
pathogen especially virus. It can find and eliminate
intracellular virus by viral peptide recognition. The finding
of CTL which is specific for HBV infection in peripheral
blood and liver tissue in patient with chronic infection
although is rare, assumed to be associated with
‘pathogenic relation’ between indolent CTL,
necroinflammatory liver disease and chronic hepatitis B.
This is the reason why CTL in HBV is considered as
double edge sword. Strong CTL response induces viral
clearance; inversely ineffective CTL response may cause
hepatocellular damage.
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CLASSIFICATION10
HBV is divided into several serotypes/genotypes
according to geographic distribution. Genotype A is
associated with good prognosis and longer survival.
Genotype C is associated with more severe course of
disease. On the other hand, genotype B is associated with
the occurrence of HCC. The mutation affects the core
gene. There are 2 gene cores HBcAg and HBeAg.
HBcAg forms nucleocapsid which essential for viral
replication and formation. HBeAg is synthesized as
alternative process of gene core, released into
circulation, nonessential for replication or induce
productive infection in vivo. HbeAg is used for clinical
practice as viral replication index, disease severity, and
therapeutic response. It is assumed to have role in HBV
life cycle.
HBeAg induces Th2 response in mice, while HBcAg
induces Th1 response. Th2 response to HBcAg is
predominant compare to Th1 response to Ag nucleus which
causes reduced Th1-specific HBcAg in vivo. It makes
viral persistent. In mice, HBeAg may induce Th1 response
including IFN and other cytokines production needed for
viral clearance.
CLINICAL COURSE OF DISEASE
Disease course in HBV infection is determined by
interaction between viral replication process and
immunologic host response. Other factors that may have
role are gender, alcohol or concurrent infection of other
hepatitis virus. Final result of HBV infection depends on
disease severity at time when replication process of HBV
is ceased.11 Final result of chronic hepatitis B infection
seemed to be dependent to length course of infection and
liver damage severity during phase 2.12 Disease course
of chronic hepatitis B is classified into 3 categories as
follows:
Immune tolerance response: during this phase, HBeAg
is positive, serum HBV DNA level is high but there is no
clinical symptoms, normal ALT and mild histologic changes.
This phase lasts for about 10 to  30 years and during this
phase, spontaneous seroconversion of HBeAg is as low
as 2% in 3 years period.
Immune clearance phase: HBV replication is reduced,
ALT level is elevated and inflammatory activity in the
liver is increased. Seroconversion of anti HBe begins with
changes of ALT. This phase usually occurs in age 15 to
35 years old.
Low replication phase: HBsAg in serum persists but
HBeAg disappear and HBV DNA can only be detected
by PCR-assay. It is commonly developed to cirrhosis
or HCC.
TREATMENT
Many kinds of drugs had been used for chronic
hepatitis B treatment both immunomodulator (IFN-α) and
antiviral (lamivudine, adefovir dipivoxil, entecavir,
emtricitabine). However, most of them had not shown
satisfactory efficacy and only small group of them had
been approved for clinical practice.13 Main goal of
treatment is to eliminate or reduce replication and thus,
stopped or decreased hepatic necroinflammation.1,7,9,14
Short term goals of treatment are to reduce
the symptoms if there is any clinical symptom, reduce
hepatic activity, prevent development of hepatic
decompensate, confirm elimination of HBeAg and or DNA
with normalization of ALT.7 Long term treatment goals
are to prevent relapse of ALT elevation, specially in
patients with hepatic decompensate, progression to
cirrhosis and or HCC.7,13
A. MONOTHERAPY
Interferon (IFN)α 1,4,7,9,11,15,16
Interferons have anti viral, anti proliferative, and
immunomodulatory effects. It can prevent penetration of
virus into hepatocyte and activate viral ribonuclease that
suppresses HBV replication. It is also considered to have
capability to increased CTL activity, stimulate NK cell
activity and increase HLA-1 protein in infected cells.
Theoretically, IFN-α is an ideal drug in the treatment of
chronic hepatitis. Long term follow-up study had shown
IFN-α therapy was beneficial for HBeAg seroconversion,
longer survival, prevent cirrhosis and HCC in
the responsive group. IFN-α treatment was given in
patient with high replication activity state (the presence
of HBeAg or HBV DNA in the serum, patient with
elevated aminotransferase or evidence of chronic
hepatitis B from liver biopsy). Absolute contraindication
of giving treatment of IFN-α are psychotic, severe
depression, pregnancy and seizure. Relative contra-
indications are history of depression, uncontrolled
diabetes mellitus, uncontrolled hypertension, retinopathy,
psoriasis, thyroiditis, and symptomatic cardiac diseases.4
IFN-α is given by subcutaneous injection with
recommended dose in adult is 5 mu/day or 10 mu, three
times per week. In children it is given 6 mu, three times
per week with maximum dose of 10 mu. It is given for
16-24 weeks in patients with positive HBeAg. Patients
with negative HBeAg should be treated for at least
12 months. Wong et al reported group of patients whom
given IFN-α treatment had higher seroconversion rate
(33% vs. 12%) and higher DNA suppression (37% vs.
17%) compare to control group.2 side effects of IFN-α in
early course of treatment is flu-like syndrome. Some
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patients had weight loss, bone marrow suppression,
at higher risk of sepsis, alopesia, thyroid dysfunction,
depression, and psychiatric disorder and need adjustment
dose or quit from IFN treatment.2,17 IFN-α may induce
autoimmune phenomenon and more than 50 patient whom
had been treated for 4 months had formed auto antibody
like anti thyroid, anti nuclear, and anti smooth muscle.18
Conventional IFN is commonly given 3 times per week
for 4-6 months. Other preparation which is under clinical
trial is pegylated interferon (Peg IFN-α 2a). Peg IFN-α
is additional branch of poliethylene glycol 40 KD in the
base of IFN-α 2a. Pharmacokinetics and
pharmacodynamics improvements occur due to pegylated
process. Phase II ongoing multi centre study had
observed 194 naïve patients whom had been given peg
IFN-α 2a once a week with dose 90 µg, 180 µg, 270 µg
and Roveron 4.5 uA for 24 weeks. All treatment doses
were considered effective because they found rapid
reduction of HBeAg compare to conventional IFN-α 2a.
Decrease of HBV DNA level was less than 1.5 log on 1st
week until 4th week and 3.5 log on 24th week
(IFN-α 0.76 log and 2.2 log). In the end of 48th week Peg
IFN-α 90 µg and 180 µg had shown 2 times higher
response rate than conventional IFN-α 2a. Those who
had been given dose of 270 µg did not showed good
result. In difficult patients (low level of ALT, high HBV
DNA level, sign of cirrhosis) showed considerable
response as well. Unwanted reactions were not
prominent and going back to normal after IFN was
stopped. However, there are still many things to
consider and more data will be needed before this drug is
recommended.19
Lamivudine (Epivir HBV, 3TC) 2,4,7,9,13,15,16,20
Lamivudine is the only direct anti viral agent that had
been approved and available in all over the world.
Lamivudine is nucleoside analog with potent inhibitory
effect on polymerase HBV. However, suppression effect
is usually not complete and that is why it would need longer
course of therapy. Studies showed that lamivudine was
effective for seroconversion of HBeAg, normalization of
ALT and histologic improvement in both Asian and
Western patients. Lai et al reported improved
necroinflammation activity in 56% patients who received
100 mg lamivudine compare to 49% who received  25 mg
and 25% who received placebo.20 Lamivudine had rapid
onset of action, so it is highly recommended for patients
with hepatic decompensate. Lamivudine had showed
satisfactory result in patients with negative HBeAg. Main
issue in lamivudine treatment is the occurrence of drug
resistant and long response maintenance. Resistant to
lamivudine is approximately 15-22% after 1 year
lamivudine treatment.8
Recommended dose for adult with normal renal
function and no HIV infection is 100 mg/day.
Recommended dose for children is 3 mg/kg BW/day and
maximum dose 100 mg/day. Patients with renal
insufficiency should be given less. Patients with HIV
infection should be given 150 mg twice daily. In general,
lamivudine should be given for 1 year and stopped if it
already had 1 year treatment and persistent seroconversion
of HBeAg (HBeAg disappear, presence of anti HBe and
HBV DNA is not detected by non-PCR method more
than 1 single examination at 2-3 months interval).
Positive response after cessation of drugs may persist
reaching 70-80%. It had been reported that 16% patients
had acute exacerbation of HBV infection after lamivudine
had been stopped.21 Dienstag et al, reported histologic
response was 52% in patients whom received lamivudine
treatment compare to 23% in placebo group. Besides,
HBeAg seroconversion was higher in the treatment group
than in placebo group (17% vs. 6%).3 Studies in Asia on
lamivudine treatment for 1 year had reported
normalization of ALT in 72% cases and 16% HBeAg
seroconversion.22
YMDD Mutation
After 9-10 months of therapy with lamivudine, it showed
there was group of patients who was resistant.
This species had undergone mutation of polymerase gene
and was called YMDD mutation. Leung had reported
incidence was nearly reaching 50% in 3 years.23
The occurrence of YMDD mutation was sometimes
accompanied by the return of HBV DNA, commonly
elevated ALT (hepatitis flare) and decompensate
condition.21 Lai reported variant incidence in 67% after
observation for 4 years. It appeared that 33% patients
with YMDD mutation might still undergo seroconversion
of HBeAg and 59% had normal ALT in the end of
examination.24
Adefovir dipivoxil2,9,13,14
Adefovir dipivoxil is active both in vivo and in vitro to
lamivudine resistant HBV. It is given for 48 weeks, 10
mg/day (oral), well-tolerated, no significant effect on
electrolyte serum and renal function. It is a phosphonate
nucleoside analog from monophosphate adenosine which
may reduce HBV DNA level in serum to 2-4 log.8
Chemical name of adefovir dipivoxil is
9{(bis [p iva loxy]metoxy)phosphinyl )metoxy)
ethyl)adenine}. In vitro, it is effective in suppress
mutant replication which is resistant to lamivudine.
Adefovir is excreted through kidney. Dose more than
10 mg is sometimes associated with nephrotoxicity
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indicated by elevation of creatinin level and decrease of
serum phosphor. Patient with underlying renal
dysfunction who receives adefovir will need more
attention if also received cyclosporine, tacrolimus,
aminoglycosides, vancomycin and NSAID. Renal
function should be monitored during adefovir therapy and
if there is decreased renal function, the dose may be
adjusted. Drug interaction increases to 23% if adefovir is
given concomitantly with ibuprofen 800 mg three times
daily. In pregnancy, experimental study on mice showed
no toxicity to embryo or no teratogenic effect found with
dose as much as 35 mg/kgbw/day. Study on rabbits
using dose 20mg/kgbw/day showed the same result.
However, trial on pregnant patients had not been done
yet. Benefit and risk ratio have to be considered very
carefully before giving treatment of adefovir.25
A research study had studied comparison between
10 mg and 30 mg of adefovir per day in 515 patients aged
16-55 years old for 1 year. Patients were recruited from
78 centers from all over the world. Inclusion criteria were
positive HBeAg at least for 6 months, minimum HBV
DNA in serum 1 million copies/ml and elevated ALT
1.2 -10 times from normal value. Prothrombine time was
not more than 1 second beyond normal level, albumin level
at least 3 mg/dL. Total bilirubin was not more than
2.5 mg/dL, creatinin level was not more than 1.5 mg/dL,
and relatively normal peripheral blood examinations.    After
48 weeks, patients were treated with adefovir had showed
histologic improvement, reduction of HBV DNA,
elimination of HBV DNA, normalization of ALT and
seroconversion of HbeAg. There were no resistant
mutants found at polymerase gene of HBV DNA.
It showed that more unwanted reactions seen in patients
received 30 mg/day. Thus, dose of 10 mg/day was
recommended for long term treatment.26
Entecavir (ETV)2,9
Entecavir is a deoxyguanine nucleoside analog which
is selective inhibitor of HBV replication and selective
activity countered HBV. Entecavir is effective for HBV
mutant which is resistant to lamivudine and have effect
30 times more potent than lamivudine in cell suppression
especially on Hep G2.2.15. Robert A De Man et al had
conducted clinical trial with placebo controlled of
42 patients who received entecavir with 4 times dose
increment (0.05, 0.1, 0.5, 1 mg).19 In all patients, there
was reduced HBV DNA serum after 4 weeks of therapy.
Entecavir inhibited HBV replication through 3 phases:
• Priming/maturation of polymerase HBV DNA
• In reverse transcriptase formation from negative chain
of HBV DNA from mRNA pre-genomic.
• Synthesis of positive chain of HBV DNA
Other studies which had compared treatment of
entecavir (0.05, 0.1, 0.5 mg) with lamivudine 100 mg
indicated entecavir with dose 0.1 and 0.5 mg was better
in viral response and HBV DNA reduced and
seroconversion of HBeAg after 22 weeks, and decreased
ALT (14%) after 24 weeks.
Emtricitabine (Coviracil/FTC)
Emtricitabine is transcriptase inhibitor deoxytidine
analog which had been proven to have potent and
selective inhibitory activity against HBV and HIV. Chemi-
cal name is FTC [( -)-2’,3’-dideoxy-5 fluoro-3’-
thiacytidine]. Pre-eliminary multicentre study using
emricitabine had been conducted in 49 patients
(screening from 92 patients) aged 18-55 years old with
positive HBsAg for minimum 3 and negative IgM HBV,
and ALT level not more than 2 times normal value.
Patients who received interferon in the last 3 months,
received other antiviral or nucleoside analog for more than
3 months or 60 days during screening period,
 including those received antiviral therapy,
immunomodulatory drug or corticosteroid were excluded.
This study was a cohort study of dose escalation   phase
I-II. Patients received 25 mg 10 mg (11 patients), 50 mg
(8 patients), 100 mg (11 patients), 200 mg (9 patients),
and 300 mg (10 patients) for 8 weeks and were observed
until the next 28 days after cessation of therapy. HBV
DNA level was checked at the beginning and
every period of drug therapy. Viral suppression was found
in all doses used and well tolerated.16 It was concluded
that further study is needed for treatment of  infection.
Pharmacokinetics study on emcitarabine reported that viral
suppression effect would be more prominent if
the starting dose given was at least 100 mg/day.27
Tenofovir disoproxil fumarate (TDF).28,29
Tenofovir R-9-(2-phosphonyl-methoxypropyl) adenine
is an acyclic nucleoside reverse transcriptase inhibitor which
had been approved by FDA. It wasusually used for HIV-1
treatment. HIV infected patients were commonly to have
concurrently HBV infection. That is why some
researchers had tried this drug on HVB infection. In vitro,
it can inhibit HBV activity including HBV variant which is
known to be lamivudine resistant. The study was conducted
for 24 weeks in 6 HIV infected patients with persistent
HBV replication although they had received interferon with
lamivudine or emcitarabine and had viral load
> 106 copies/ml. Patients were received TDF 300 mg/day
orally beside the standard regimen of anti viral therapy.
They were observed on 4th, 8th, 12th and 24th week. TDF
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was well tolerated during study period. On the 12th week, it
was found reduced HBV load in serum 3.1 log10 copies/ml
(7.9 ± 0.6 log10 convert to 4.8 ± 1.0 log10 copies/ml), until
24th week HBV load reduced to 3.6 ± 0.4 log10.
Other study was conducted involving 20 homosexual
HIV infected patients aged 22-52 years old with positive
HBV and HBeAg. Patients received TDF 245 mg (oral)
for 52 weeks. Examinations were conducted on 4th, 12th,
and 24th week, then it was continued to be checked every
12 weeks. On 24th week, 2 patients showed
seroconversion to positive anti HBe, and on 52nd week,
5 patients (25%) had also showed seroconversion. It was
concluded from both these studies that TDF was good
for positive HBV treatment in HIV positive patients who
was resistant to lamivudine.
B. COMBINATION THERAPY 9,20
Monotherapy after 12 months was usually followed by
viral resistance in about 15% of patients per year.
Combination therapy has synergistic anti viral effect,
reduced the risk of resistance and minimizing toxicity.
Combination therapy consists of 2 or more drugs given
concurrently. First thing needs to know is that every drug
must have been proved well tolerated to give individually.
Time of giving drug should be carefully observed, whether
these drugs can be given at the same time or one drug at a
time and which drug should be given first. Drugs used for
combination therapy are as follows:
IFN-α and Lamivudine
IFN-α and lamivudine would be more effective and give
seroconversion rate of HBeAg higher than monotherapy.
Schalm et al studied 230 patients with chronic HBV
infection and reported seroconversion rate of HBeAg on
52nd week was 29% for combination therapy, 19% for
IFN-α monotherapy and 18% for lamivudine
monotherapy.20 Lamivudine was given for 52 weeks while
IFN-α given for 16 weeks.30 In combination therapy,
lamivudine was given for 24 weeks and IFN-α was given
on 16th week.30 Barbaro et al, reported 94% - 96% from
151 patients showed improvement compare to those who
only received monotherapy. Relapse of HBeAg and HBV
DNA was found higher in 7% patients for combination
therapy and 20% in those whom received monotherapy of
lamivudine.31
Lamividune and adefovir dipivoxil.13
Combination therapy of lamivudine and adefovir
dipivoxil had promising result to reduce drug resistance.
Use of lamivudine and adefovir were evaluated in
2 studies which were presented in AASLD (American
Association for the Study of the Liver) 2001 in lamivudine
resistant patients, decompensate cirrhosis or recurrent
HBV infection after liver transplantation. Suppression of
HBV replication was reduced in all patients and most of
them had showed improvement of biochemical and
clinical status. Unwanted reactions found were very mild.
Clinical improvement indicated that combination therapy
is the treatment of choice in patients who have liver
disease and need long term therapy.31
CONCLUSION
IFN-α has immunomodulator property and is
effective to inhibit viral replication and eradicate carrier
condition in chronic HBV infection. Lamivudine is oral
anti viral drug which has potent inhibition effect but
commonly induce drug resistance and acute
exacerbation after cessation of therapy.
In the treatment of chronic HBV infection,
combination therapy should be considered if there is no
sufficient response to monotherapy. To date,
the treatment of chronic HBV infection had not showed
satisfying result yet. However, ongoing clinical studies
have been conducted and may contribute for
development in the treatment of chronic HBV.
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